Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93

Breast

Volumn 10, Issue , 2001, Pages 130-138

  Thurlimann B ^a   Price, K N ^a   Castiglione, M ^a   Coates, A S ^a   Goldhirsch, A ^a   Gelber, R D ^a   Forbes, J ^a   Holmberg, S ^a   Veronesi, A ^a   Bernhard, J ^a   Zahrich, D ^a  

^a International Breast Cancer Study Group Coordinating Center   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; GONADORELIN ANTAGONIST; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL RESEARCH; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MORTALITY; MULTICENTER STUDY; OVARIECTOMY; OVARY FUNCTION; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK; SELF CONCEPT; SIDE EFFECT; STATISTICAL ANALYSIS; TUMOR VOLUME;

EID: 0034924722     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(16)30022-4     Document Type: Article

References (21)

1. On the treatment of inoperable cases of carcinoma of the mamma: Suggestion for a new method of treatment, with illustrative cases
2. Ovarian ablation in early breast cancer: An overview of randomised trials
3. Meeting highlights: International consensus panel on the treatment of primary breast cancer
4. The emerging role of hormonal ablation as adjuvant therapy in node-positive and node-negative pre/perimenopausal patients
5. Comparison of adjuvant therapy with tamoxifen and goserelin versus CMF in premenopausal stage I and II hormone responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5
6. Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP)
7. Systemic adjuvant treatment for premenopausal node-negative breast cancer
8. Tamoxifen for early breast cancer: An overview of the randomised trials
9. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials
10. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101)
11. Complete endocrine blockade with tamoxifen and goserelin is superior to CMF in the adjuvant treatment of premenopausal. Lymph-node-positive and -negative patients with hormone-responsive breast cancer
12. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomised trial by the Cancer Research Campaign (CRC)
13. Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer
14. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer
15. Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach
16. Nonparametric estimation from incomplete observations
17. The natural duration of cancer
18. Evaluation of survival data and two new rank order statistics arising in its consideration
19. Regression models and life-tables
20. The ZIPP trial of adjuvant zoladex in premenopausal patients with early breast cancer: An update at five years